The headline reads as positive (87% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › GILD
Gilead Sciences, Inc. (GILD) stock analysis
BUY 42% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Gilead Sciences, Inc. (GILD) BUY with 42% confidence at a price of $165.61. That means most of the technical, fundamental, money-flow and news signals point to upside.
Analysed price$165.61
Technical picture
The 14-day RSI is 69, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is about normal (1.4x the 20-day average).
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $154.51 and the swing low is $119.92; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 2.35, which looks expensive relative to its growth.
The company reports a profit margin of -10.6% and revenue growth of +10.2%.
In its latest quarter it earned $-6.75 per share, which beat the $-7.25 analysts expected, with revenue +10.2% year over year.
Wall Street's average rating is 1.7 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $160.19.
Trade plan from the model
The model's long / bullish plan uses an entry near $165.61, a target of $179.13 (+8.2%) and a stop-loss at $157.06 (-5.2%).
That is a reward-to-risk ratio of about 1.6 to 1: the potential gain is larger than the potential loss.
The plan has a time limit: reassess by Nov 19, 2026 whatever the price does.
Entry$165.61
Target$179.13
Stop-loss$157.06
Reassess byNov 19, 2026
Research notes
Gilead’s bull case centers on resilient Biktarvy-led HIV cash flow, growing oncology potential from Trodelvy and cell therapy, and longer-term upside from lenacapavir/Yeztugo; recent oncology data has led some analysts to view the shares as materially undervalued. The bear case is that GILD’s rally has outpaced fundamentals, with expected roughly flat third-quarter revenue and lower EPS, plus pricing and funding pressure in HIV, slowing Yescarta adoption, clinical execution risk, acquisition-related dilution, and leverage. Major recent catalysts include the $1.275 billion PepStar acquisition agreement, positive oncology-trial attention, Canadian public-reimbursement terms for LYVDELZI, and the upcoming third-quarter earnings report. Shares reached a 52-week high near $160.83 on October 28 and closed around $161.44 on October 29, leaving valuation and earnings execution as key near-term tests.
The model's one-paragraph read
Leans BUY — composite score +0.42 (BUY). Technicals: RSI 69.14, MACD bullish, price above SMA50. Fundamentals: PEG 2.35, margin -10.6%, revenue growth 10.2%. Financial results: YoY revenue +10.2%, last EPS surprise +6.9%. Smart Money Concepts: BOS bullish (trend continuation). FinGPT news read: neutral. Internet research: Gilead’s **bull case** centers on resilient Biktarvy-led HIV cash flow, growing oncology potential from Trodelvy and cell therapy, and longer-term upside from lenacapavir/Yeztugo; recent oncology data has led some analysts to view the shares as materially undervalued. The **bear case** is that GILD’s rally has outpaced fundamentals, with expected roughly flat third-quarter revenue and lower EPS, plus pricing and funding pressure in HIV, slowing Yescarta adoption, clinical execution risk, acquisition-related dilution, and leverage. Major recent catalysts include the $1.275 billion PepStar acquisition agreement, positive oncology-trial attention, Canadian public-reimbursement terms for LYVDELZI, and the upcoming third-quarter earnings report. Shares reached a 52-week high near $160.83 on October 28 and closed around $161.44 on October 29, leaving valuation and earnings execution as key near-term tests. Suggested levels: entry $165.61, target $179.13, stop-loss $157.06, exit by 2026-11-19 (21-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for GILD
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | BUY | 42% | $165.61 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on GILD
Oct 29, 2026 · How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade
- Oct 29, 2026: Gilead hikes 2026 sales outlook, says Medicare cuts Biktarvy price by 38% starting in 2028 (Reuters)
- Oct 29, 2026: Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength (The Wall Street Journal)
- Oct 29, 2026: How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade (Investor's Business Daily)
- Oct 29, 2026: Gilead's HIV Franchise Powers Earnings Beat. The Rest Is a Work in Progress. (Barrons.com)
Frequently asked questions
Is GILD a buy right now?
As of Oct 29, 2026, our automated model rates Gilead Sciences, Inc. (GILD) BUY with 42% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for GILD?
The model's most recent plan targets $179.13 with a stop-loss at $157.06, from an entry near $165.61.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.